Vestor Capital LLC Sells 20,515 Shares of Eli Lilly and Company (NYSE:LLY)

Vestor Capital LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 44.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 25,305 shares of the company’s stock after selling 20,515 shares during the period. Eli Lilly and Company accounts for about 1.5% of Vestor Capital LLC’s portfolio, making the stock its 14th largest position. Vestor Capital LLC’s holdings in Eli Lilly and Company were worth $19,535,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Principal Financial Group Inc. lifted its position in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter worth about $10,115,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Eli Lilly and Company in the third quarter worth about $1,449,000. Thompson Siegel & Walmsley LLC raised its position in Eli Lilly and Company by 18.8% during the third quarter. Thompson Siegel & Walmsley LLC now owns 2,549 shares of the company’s stock valued at $2,258,000 after purchasing an additional 403 shares during the period. Finally, HealthInvest Partners AB raised its position in Eli Lilly and Company by 12.6% during the third quarter. HealthInvest Partners AB now owns 30,564 shares of the company’s stock valued at $27,078,000 after purchasing an additional 3,420 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Down 0.4 %

Eli Lilly and Company stock opened at $839.44 on Friday. The business has a fifty day moving average of $835.99 and a two-hundred day moving average of $839.87. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm has a market cap of $795.93 billion, a P/E ratio of 71.69, a P/E/G ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.